RT Journal Article
SR Electronic
T1 Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.14.22270915
DO 10.1101/2022.03.14.22270915
A1 Efstratios Gavriilidis
A1 Christina Antoniadou
A1 Akrivi Chrysanthopoulou
A1 Maria Ntinopoulou
A1 Andreas Smyrlis
A1 Iliana Fotiadou
A1 Nikoleta Zioga
A1 Dionysios Kogias
A1 Anastasia-Maria Natsi
A1 Christos Pelekoudas
A1 Evangelia Satiridou
A1 Stefania-Aspasia Bakola
A1 Charalampos Papagoras
A1 Ioannis Mitroulis
A1 Paschalis Peichamperis
A1 Dimitrios Mikroulis
A1 Vasileios Papadopoulos
A1 Panagiotis Skendros
A1 Konstantinos Ritis
YR 2022
UL http://medrxiv.org/content/early/2022/03/15/2022.03.14.22270915.abstract
AB COVID-19-related severe respiratory failure (SRF) leads to mechanical ventilation increasing the in-hospital mortality substantially. Abundancy of lung fibroblasts (LFs) in injured lung tissue has been associated with the progression of respiratory failure in COVID-19. Aiming to reduce mortality in patients with SRF (PaO2/FiO2<100 mmHg) and considering the multi-mechanistic nature of severe COVID-19 pathogenesis, we applied a combined rescue treatment (COMBI) on top of standard-of-care (SOC: dexamethasone and heparin) comprised inhaled DNase to dissolve thrombogenic neutrophil extracellular traps, plus agents against cytokine-mediated hyperinflammation, such as anti-IL-6 receptor tocilizumab and selective JAK1/2 inhibitor baricitinib. COMBI (n=22) was compared with SOC (n= 26), and with two previously and consecutively used therapeutic approaches, including either IL-1 receptor antagonist anakinra (ANA, n=19), or tocilizumab (TOCI, n=11), on top of SOC. In parallel, evaluation of immunothrombosis was assessed in vitro in human LFs, treated with the applied therapeutic agents upon stimulation with COVID-19 plasma. COMBI was associated with lower in-hospital mortality (p=0.014) and intubation rate (p=0.013), shorter duration of hospitalization (p=0.019), and prolonged overall survival after a median follow-up of 110±4 days (p=0.003). In vitro, COVID-19 plasma markedly induced tissue factor/thrombin pathway in LFs, while this effect was inhibited by the immunomodulatory agents of COMBI providing a mechanistic explanation for the clinical observations. These results suggest the design of randomized trials using combined immunomodulatory therapies in COVID-19-associated SRF targeting multiple interconnected pathways of immunothrombosis.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05279391Funding StatementThis study was supported by the Greek General Secretariat for Research and Technology (GSRT), Research & Innovation Programme CytoNET, grant MIS-5048548 and by GSRT, Regional Excellence Programme InTechThrace, grant MIS-5047285.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol design was approved by the local scientific and ethics committees and institutional review board of the University Hospital of Alexandroupolis (Ref. No. 87/08-04-2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript